CASE REPORT

Therapeutic Plasmapheresis in Amiodarone-Induced Thyrotoxicosis Resistant to Medical Therapy
Medikal Tedaviye Dirençli Amiodaron ile İlişkili Tirotoksikozda Terapötik Plazmaferez Tedavisi
Received Date : 01 Jul 2019
Accepted Date : 20 Oct 2019
Available Online : 13 Nov 2019
Doi: 10.25179/tjem.2019-66735 - Makale Dili: EN
Turk J Endocrinol Metab 2019;23:253-258
Bu makale, CC BY-NC-SA altında lisanslanmış açık erişim bir makaledir.
ABSTRACT
Amiodarone treatment is associated with thyroid dysfunction resulting in life-threatening thyrotoxicosis. Thyroidectomy may be required if medication is contraindicated or thyroid dysfunction is resistant to the treatment. Therapeutic plasmapheresis (TP) may thus be considered to ensure perioperative euthyroidism, prevent thyroid storm and decrease the risk in surgery. In this case report, we discussed the potential option of TP treatment in the surgical preparation of a patient with Type 1 amiodarone-induced thyrotoxicosis resistant to antithyroid therapy.
ÖZET
Amiodaron tedavisi tiroid disfonksiyonu ve hayatı tehdit eden tirotoksikoz ile ilişkilidir. Tıbbi olarak dirençli olgularda veya medikal tedavinin kontrendike olduğu durumlarda tiroidektomi gerekebilir. Perioperatif ötiroidizmi sağlamak, tiroid krizi ve cerrahi riskini azaltmak için terapötik plazmaferez (TP) düşünülebilir. Bu olgu sunumundai Tip 1 amiodaron ilişkili tirotoksikozu olan ancak antitiroid tedaviye dirençli olguda cerrahi hazırlıkta TP tedavisinin bir seçenek olabileceği tartışılmaktadır.
KAYNAKLAR
  1. Iervasi G, Clerico A, Bonini R, Manfredi C, Berti S, Ravani M, Palmieri C, Carpi A, Biagini A, Chopra IJ. Acute effects of amiodarone administration on thyroid function in patients with cardiac arrhythmia. J Clin Endocrinol Metab. 1997;82(1):275-80. [Crossref]  [PubMed] 
  2. Rao RH, McCready VR, Spathis GS. Iodine kinetic studies during amiodarone treatment. J Clin Endocrinol Metab. 1986;62:563-8. [Crossref]  [PubMed] 
  3. Harjai KJ. Effects of amiodarone on thyroid function. Vol. 126. Ann Intern Med. 2013;63. [Crossref]  [PubMed] 
  4. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med. 1991;91:507-511. [Crossref] 
  5. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab. 1996;81:2930-2933. [Crossref]  [PubMed] 
  6. Bartalena L, Grasso L, Brogioni S, Aghini-Lombardi F, Braverman LE, Martino E. Serum interleukin-6 in amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 1994;78:423-427. [Crossref]  [PubMed] 
  7. Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Dydejczyk A, Links TP, Vanderpump M. 2018 European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction. Eur Thyroid J. 2018;7:55-66. [Crossref]  [PubMed]  [PMC] 
  8. Newnham HH, Topliss DJ, Le Grand BA, Chosich N, Harper RW, Stockýgt JR. Amiodarone-induced hyperthyroidism: assessment of the predictive value of biochemical testing and response to combined therapy using propylthiouracil and potassium perchlorate. Aust N Z J Med. 1988;18:37-44. [Crossref]  [PubMed] 
  9. Yiu KH, Jim MH, Siu CW, Lee CH, Yuen M, Mok M, Shea YF, Fan K, Tse HF, Chow WH. Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. J Clin Endocrinol Metab. 2009;94:109-114. [Crossref]  [PubMed] 
  10. Tomisti L, Materazzi G, Bartalena L, Rossi G, Marchello A, Moretti M, De Napoli L, Mariotti R, Miccoli P, Martino E, Bogazzi F. Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. J Clin Endocrinol Metab. 2012;97:3515-3521. [Crossref]  [PubMed] 
  11. Bartges JW. Therapeutic plasmapheresis. Vol. 12. Seminars in Veterinary Medicine and Surgery-Small Animal. Philadelphia, PA, USA: Elsevier; 1997;170-7. [Crossref] 
  12. Lukomskii GI, Alekseeva ME, Ivanova NA, Kabanova GM, Tatsievskii VA, Saulko AM. Plasmapheresis in preoperative care of patients with thyrotoxicosis. Khirurgiia (Mosk). 1991;102-105.
  13. Balzano S, Sau F, Bartalena L, Ruscazio M, Balestrieri A, Cherchi A, Maritno E. Diagnosis of amiodarone-iodine-induced thyrotoxicosis (AIIT) associated with severe nonthyroidal illness. J Endocrinol Invest. 1987;10:589-591. [Crossref]  [PubMed] 
  14. Bogazzi F, Bartalena L, Martino E. Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2010;95:2529-2535. [Crossref]  [PubMed] 
  15. Tomisti L, Urbani C, Rossi G, Latrofa F, Sardella C, Manetti L, Lupi I, Marcocci C, Bartalena L, Curzio O, Martino E, Bogazzi F. The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis. J Endocrinol Invest. 2016;39:585-591. [Crossref]  [PubMed] 
  16. Theodoraki A, Vanderpump MPJ. Thyrotoxicosis associated with the use of amiodarone: the utility of ultrasound in patient management. Clin Endocrinol (Oxf). 2016;84:172-176. [Crossref]  [PubMed] 
  17. Piga M, Cocco MC, Serra A, Boi F, Loy M, Mariotti S. The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Eur J Endocrinol. 2008;159:423-429. [Crossref]  [PubMed] 
  18. O'Sullivan AJ, Lewis M, Diamond T. Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. Eur J Endocrinol. 2006;154:533-536. [Crossref]  [PubMed] 
  19. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003;108:977-982. [Crossref]  [PubMed] 
  20. Kaderli RM, Fahrner R, Christ ER, Stettler C, Fuhrer J, Martinelli M, Vogt A, Seiler C. Total thyroidectomy for amiodarone-induced thyrotoxicosis in the hyperthyroid state. Exp Clin Endocrinol Diabetes. 2015;124:45-48. [Crossref]  [PubMed] 
  21. Ward DM. Conventional apheresis therapies: a review. J Clin Apher. 2011;26:230-238. [Crossref]  [PubMed] 
  22. Keklik M, Kaynar L, Yilmaz M, Sivgin S, Solmaz M, Pala C, Aribas S, Akyol G, Unluhizarci K, Cetin M, Eser B, Unal A. The results of therapeutic plasma exchange in patients with severe hyperthyroidism: a retrospective multicenter study. Transfus Apher Sci. 2013;48:327-330. [Crossref]  [PubMed] 
  23. Zhu L, Zainudin SB, Kaushik M, Khor LY, Chng CL. Plasma exchange in the treatment of thyroid storm secondary to type II amiodarone-induced thyrotoxicosis. Endocrinol Diabetes Metab Case Rep. 2016;2016:160039. [Crossref]  [PubMed]  [PMC] 
  24. Schlienger JL, Faradji A, Sapin R, Blickle JF, Chabrier G, Simon C, Imler M. Treatment of severe hyperthyroidism by plasma exchange. Clinical and biological efficacy. 8 cases. Presse Med. 1985;14: 1271-1274.
  25. Ashkar FS, Katims RB, Smoak WM 3rd, Gilson AJ. Thyroid storm treatment with blood exchange and plasmapheresis. JAMA. 1970;214:1275-1279. [Crossref]  [PubMed] 
  26. Pasimeni G, Caroli F, Spriano G, Antonini M, Baldelli R, Appetecchia M. Refractory thyrotoxicosis induced by iodinated contrast agents treated with therapeutic plasma exchange. A case report. J Clin Apher. 2008;23:92-95. [Crossref]  [PubMed] 
  27. Yamamoto J, Dostmohamed H, Schacter I, Ariano RE, Houston DS, Lewis B, Knoll C, Katz P, Zarychanski R. Preoperative therapeutic apheresis for severe medically refractory amiodarone-induced thyrotoxicosis: a case report. J Clin Apher. 2014;29:168-170. [Crossref]  [PubMed] 
  28. Simsir IY, Ozdemir M, Duman S, Erdogan M, Donmez A, Ozgen AG. Therapeutic plasmapheresis in thyrotoxic patients. Endocrine. 2018;62:144-148. [Crossref]  [PubMed]